SL Swiss Lipid Navigator
Demonstration prototype — synthetic data only, simplified rules, not for clinical use.
Step 10 of 10 · Decision support

Summary

What this step shows

All results for this patient in one view, with the reasoning behind each step. Update any value and the results are recalculated.

Claire Rochat
DEMO-3 · 67 years · Female · born 26.05.1959 · LDL-C measured 30.08.2026
Update lab values
Clinical pathwaySecondary Prevention
Risk categoryVery High
LDL-C (current)2.3 mmol/L
LDL-C target<1.4 mmol/L
Current treatmentHigh-intensity statin (Rosuvastatin 40 mg) + ezetimibe
Recommended next stepConsider PCSK9 inhibitor pathway (e.g. evolocumab / alirocumab)
Swiss reimbursement Eligible
Reasoning by step
  1. Step 5 — Clinical pathway View details →
    Secondary Prevention

    Patient has established atherosclerotic cardiovascular disease. This automatically places them on the secondary-prevention pathway — no risk score is needed to classify risk.

  2. Step 6 — Cardiovascular risk View details →
    Very High

    Per standard risk stratification, established atherosclerotic cardiovascular disease is automatically classified Very High risk — no numeric score is calculated.

  3. Step 7 — LDL-C target View details →
    <1.4 mmol/L

    Very High risk → target <1.4 mmol/L (and ≥50% reduction from baseline where baseline is known).

  4. Step 8 — Treatment plan View details →
    Consider PCSK9 inhibitor pathway (e.g. evolocumab / alirocumab)

    Maximally tolerated statin + ezetimibe therapy (or documented intolerance) for ≥3 months, still above target — clinically appropriate to consider a PCSK9 inhibitor. This triggers the Swiss Reimbursement Engine.

  5. Step 9 — Swiss reimbursement View details →
    Eligible

    All demo reimbursement criteria are met.

Demonstration output based on simplified rules — not clinical advice. Generated 02.11.2026 17:30.

← Swiss reimbursement
Back to patients →